LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Gene Panel Predicts Damage in Donated Kidneys

By LabMedica International staff writers
Posted on 04 Aug 2016
Print article
Image: The Aperio Scanscope CS whole slide scanner system (Photo courtesy of Leica).
Image: The Aperio Scanscope CS whole slide scanner system (Photo courtesy of Leica).
Kidney transplantation is a life-extending procedure and a panel of genes has been identified that can help predict whether a transplanted kidney will later develop fibrosis, an injury which can cause the organ to fail.

Chronic allograft damage, or interstitial fibrosis and tubular atrophy of unknown cause, is the major cause of allograft loss in the first year after transplantation. Clinical and histological events associated with interstitial fibrosis and tubular atrophy are poorly predictive of allograft loss, making it difficult to identify allografts that could benefit from early interventions to prevent progression of fibrosis.

A multicenter team of scientists led by those at the Icahn School of Medicine at Mount Sinai (New York, NY, USA) prospectively collected biopsies from 204 renal allograft recipients with stable renal function three months after transplantation. They used microarray analysis to investigate gene expression in 159 of these tissue samples. Their aim was to genes that correlated with the Chronic Allograft Damage Index (CADI) score at 12 months, but not fibrosis at the time of the biopsy. The CADI score is a measure of the level of fibrosis in the transplanted kidney.

Two tissue cores were taken from each of the three-month and one year protocol renal biopsies of the Genomics of Chronic Allograft Rejection (GoCAR) cohort. One core was processed for histology and the other core was processed for messenger ribonucleic acid (mRNA). Immunohistochemistry was done on an automated stainer on paraffin sections stained with a rabbit polyclonal antibody (American Research Products, Inc, Waltham, MA, USA). All slides were scanned with an Aperio CS whole slide scanner (Leica, Wetzlar, Germany) and high-resolution digital images and archived in an image database. Total RNA was extracted from percutaneous graft biopsy samples, processed onto gene chips and scanned using GeneChip Scanner 7G (Affymetrix Inc, Santa Clara, CA, USA).

The investigators identified a set of 13 genes that was independently predictive for the development of fibrosis at one year. The routine pathological variables were unable to identify which histologically normal allografts would progress to fibrosis whereas the predictive gene set accurately discriminated between transplants at high and low risk of progression. The rate of correlation of the identified gene set with damage was greater than the clinico-pathological variables currently used in practice to identify kidney transplant recipients at risk of allograft damage and loss.

Barbara Murphy, MD, the study leader, said, “By helping us better understand the causes of damage to transplanted kidneys; this study has the potential to change how we monitor and manage all renal transplant patients. The study offers the potential to identify renal transplant recipients at risk for a loss of the new organ prior to the development of irreversible damage. This would mean that doctors might eventually have the opportunity to change the therapeutic treatment approach in order to prevent fibrosis from progressing at all.” The study was published on July 22, 2016, in the journal The Lancet.

Related Links:
Icahn School of Medicine at Mount Sinai
American Research Products
Leica
Affymetrix
Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Immunofluorescence Analyzer
MPQuanti

Print article

Channels

Clinical Chemistry

view channel
Image: The research team has developed the uCR-Chip device to enhance kidney function testing (Photo courtesy of University of Manitoba)

Low-Cost Portable Screening Test to Transform Kidney Disease Detection

Millions of individuals suffer from kidney disease, which often remains undiagnosed until it has reached a critical stage. This silent epidemic not only diminishes the quality of life for those affected... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.